CR10014A - DERIVATIVES OF 3-ALQUILAZETIDINA SUBSTITUTED WITH HETEROCICLES. - Google Patents

DERIVATIVES OF 3-ALQUILAZETIDINA SUBSTITUTED WITH HETEROCICLES.

Info

Publication number
CR10014A
CR10014A CR10014A CR10014A CR10014A CR 10014 A CR10014 A CR 10014A CR 10014 A CR10014 A CR 10014A CR 10014 A CR10014 A CR 10014A CR 10014 A CR10014 A CR 10014A
Authority
CR
Costa Rica
Prior art keywords
alquilazetidina
heterocicles
derivatives
substituted
receptor
Prior art date
Application number
CR10014A
Other languages
Spanish (es)
Inventor
Robert K Baker
Jeffrey J Hale
Shouwu Miao
Kathleen M Rupprecht
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CR10014A publication Critical patent/CR10014A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Compuestos novedosos de la fórmula estructural (I) son antagonistas y/o agonistas inversos del receptor cannabinoide-1 (CB1) y son útiles en el tratamiento, prevención y supresión de enfermedades mediadas por el receptor CB1. Los compuestos de la presente invención son útiles como fármacos que actúan a nivel central en el tratamiento de psicosis, deficiencias de la memoria, trastornos cognitivos, enfermedad de Alzheimer, migraña, neuropatía, trastornos neuroinflamatorios que incluyen esclerosis múltiple.Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the cannabinoid-1 receptor (CB1) and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as drugs that act centrally in the treatment of psychosis, memory deficiencies, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuroinflammatory disorders that include multiple sclerosis.

CR10014A 2005-11-28 2008-05-22 DERIVATIVES OF 3-ALQUILAZETIDINA SUBSTITUTED WITH HETEROCICLES. CR10014A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74018305P 2005-11-28 2005-11-28

Publications (1)

Publication Number Publication Date
CR10014A true CR10014A (en) 2008-07-29

Family

ID=37779312

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10014A CR10014A (en) 2005-11-28 2008-05-22 DERIVATIVES OF 3-ALQUILAZETIDINA SUBSTITUTED WITH HETEROCICLES.

Country Status (15)

Country Link
EP (1) EP1954692A1 (en)
KR (1) KR20080073721A (en)
AR (1) AR058199A1 (en)
BR (1) BRPI0619018A2 (en)
CR (1) CR10014A (en)
DO (1) DOP2006000261A (en)
EC (1) ECSP088477A (en)
IL (1) IL191586A0 (en)
MA (1) MA30086B1 (en)
NO (1) NO20082919L (en)
PE (1) PE20070647A1 (en)
RU (1) RU2008126248A (en)
SV (1) SV2009002917A (en)
TW (1) TW200804317A (en)
WO (1) WO2007062193A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
EP2212313A2 (en) * 2007-10-24 2010-08-04 Merck Sharp & Dohme Corp. Synthesis and crystalline forms of cb-1 antagonist/inverse agonist
US9440948B2 (en) 2010-09-03 2016-09-13 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (en) 2011-03-08 2016-06-01 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805810B1 (en) * 2000-03-03 2002-04-26 Aventis Pharma Sa PHARMACEUTICAL COMPOSITIONS CONTAINING 3- AMINO-AZETIDINE DERIVATIVES, THE NEW DERIVATIVES AND THEIR PREPARATION
FR2805818B1 (en) * 2000-03-03 2002-04-26 Aventis Pharma Sa AZETIDINE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2805817B1 (en) * 2000-03-03 2002-04-26 Aventis Pharma Sa PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND THEIR PREPARATION
WO2005000809A1 (en) * 2003-06-11 2005-01-06 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
JP2008540426A (en) * 2005-05-02 2008-11-20 メルク エンド カムパニー インコーポレーテッド Combination of dipeptidyl peptidase IV inhibitor and cannabinoid CB1 receptor antagonist for the treatment of diabetes and obesity

Also Published As

Publication number Publication date
SV2009002917A (en) 2009-02-19
ECSP088477A (en) 2008-06-30
RU2008126248A (en) 2010-01-10
BRPI0619018A2 (en) 2016-11-29
EP1954692A1 (en) 2008-08-13
NO20082919L (en) 2008-08-27
PE20070647A1 (en) 2007-08-11
MA30086B1 (en) 2008-12-01
AR058199A1 (en) 2008-01-23
KR20080073721A (en) 2008-08-11
TW200804317A (en) 2008-01-16
DOP2006000261A (en) 2007-07-15
WO2007062193A1 (en) 2007-05-31
IL191586A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
CR10014A (en) DERIVATIVES OF 3-ALQUILAZETIDINA SUBSTITUTED WITH HETEROCICLES.
CR7432A (en) ACTIVE REPLACED AMIDAS OF THE CANABINOID RECEIVER-1
NI201100084A (en) ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS.
DK2049529T3 (en) Substituted diazepan-orexin receptor antagonists
GT200900300A (en) PIRIDIL PIPERIDINE ANTAGONISTS OF THE OREXINE RECEPTOR
ATE394400T1 (en) BICYCLIC ANILIDE SPIROHYDANTOINS AS CGRP RECEPTOR ANTAGONISTS
ATE493412T1 (en) SPIROHYDANTOIN-ARYL-CGRP RECEPTOR ANTAGONISTS
CY1111977T1 (en) PEPERIDIN-4-YL-PYRIDAZIN-3-YLAMINE DERIVATIVES AS HIGHLY DISTRIBUTED DOPAMIN COMPONENTS 2
DE602005020655D1 (en) Carboxamide-spirolactam CGRP Receptor Antagonists
ATE535514T1 (en) CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS
CY1113798T1 (en) Substituted Diazepane Compounds as Orexin Receptor Competitors
ATE537170T1 (en) CGRP RECEPTOR ANTAGONISTS
CR20130214A (en) ANTIGONISTS OF THE RECEIVER OF THE CGPR OF PIPERIDINONA CARBOXAMIDA AZAINDANO
UA100974C2 (en) Substituted diazepan compounds as orexin receptor antagonists
CL2008002506A1 (en) Compounds derived from substituted benzimidazole, preparation process, pharmaceutical composition, useful in the treatment of diseases modulated with antagonists of the fxr receptor, in particular for the treatment of increased levels of lipids and / or cholesterol, atherosclerotic disease, diabetes, cancer, parkinson's , Alzheimer's.
AR036303A1 (en) ASSOCIATION OF A CB1 RECEIVER ANTAGONIST WITH A PRODUCT THAT ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND ITS USE FOR THE TREATMENT OF PARKINSON'S DISEASE
CY1113820T1 (en) 4-ALKOXYPYRIDAZINE PRODUCER AS HIGHLY DISTRIBUTED DOPAMINE RECEPTOR COMPONENTS 2
ATE466853T1 (en) CGRP RECEPTOR ANTAGONISTS
CY1112227T1 (en) PEPERININYLAMINE-PYRASINS AND THEIR USE OF HIGHLY DISTRIBUTED DOPAMIN COMPONENTS 2
NZ747778A (en) Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist
MX2017012677A (en) Use of quinoxaline 1,4-di-n-oxide ester derivatives for the treatment of giardiasis as anti-giardia-lamblia agents.
CL2010000998A1 (en) Compounds derived from arylsulfonyl pyrazolin carboxamidine, 5-ht6 antagonists; Preparation process; intermediary compounds; pharmaceutical composition; and its use for the treatment or prophylaxis of diseases such as psychosis, epilepsy, parkinson's disease, migraine and Alzheimer's disease.
TH1701007172A (en) Ethylene derivatives
CL2011000234A1 (en) Compounds derived from substituted cyclohexylamide, corticotropin-releasing factor receptor antagonist (crf-1); pharmaceutical composition; pharmaceutical combination; and its use for the treatment and / or prevention of gastrointestinal, depressive disorders, schizophrenia, parkinson's, inflammation, obesity, among others.
NI200800105A (en) ANTAGONISTS OF RAPID DISSOCIATION DOPAMINE RECEPTORS 2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)